Indian drugmaker Lupin and global private equity firms TPG Capital and EQT are in advanced discussions to acquire Vitabiotics, the UK-based vitamins and nutraceuticals company owned by the Lalvani family, in a potential transaction that could value the business at around £1 billion (about $1.25 billion). The talks come as Vitabiotics, known for flagship brands such as Wellwoman, Wellman and Pregnacare, revives a formal sale process amid strong global demand for nutrition and wellness products.
People familiar with the matter indicated that Lupin is exploring the deal in partnership with financial sponsors as it looks to deepen its presence in the global consumer health and nutraceuticals segment. A successful acquisition would give Lupin access to Vitabiotics’ strong UK base, international distribution network and diversified portfolio of vitamin and mineral supplements with significant brand equity across Europe, the Middle East, Asia and other key markets.
Vitabiotics has a long-standing India presence through Meyer Vitabiotics, which markets and distributes several of the group’s leading brands in the country. Meyer Organics, part of the Meyer Vitabiotics group, operates as a prominent nutraceutical and pharmaceutical company in India, with a portfolio spanning bone health, women’s health, immunity, and nutrition-focused products, as well as strong engagement with healthcare professionals through medical education and disease awareness initiatives. Any change in ownership of Vitabiotics at the global level is expected to be closely watched in the Indian market, where Meyer Vitabiotics has built substantial brand visibility and distribution reach over the years.
Vitabiotics is working with advisers to assess interest from both strategic buyers and private equity funds, with the indicative valuation understood to be anchored near the £1 billion mark. The Lalvani family, which founded and continues to lead the company, is evaluating options around stake size and future involvement in the business, including the possibility of retaining a minority interest alongside a new strategic or financial partner.
If concluded, the deal would add to a growing pipeline of large transactions in the pharma and healthcare space, where Indian companies and global investors are increasingly using M&A to build scale, secure strong consumer brands and expand geographically. For Lupin, a tie-up with Vitabiotics would accelerate diversification beyond prescription generics into branded consumer health, while potentially opening fresh synergies with Meyer Vitabiotics in India and other emerging markets.
Source acknowledgement: This article draws on information and deal details reported by The Economic Times.
